IRCT20230123057193N4 IRCT 2024-10-24 Research assistant of Tehran University of Medical Sciences The effect of L-arginine supplementation on the levels of antioxidative enzymes and inflammatory factors in patients with Metabolic dysfunction-associated steatotic liver disease(MASLD) The effect of L-arginine supplementation on the levels of antioxidative enzymes and inflammatory factors in patients with Metabolic dysfunction-associated steatotic liver disease(MASLD) 2024-10-22 anticipated 44 Complete https://irct.ir/trial/79247 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: The study subjects will be divided into blocks based on gender and BMI and then will be randomly divided into two intervention groups with arginine and placebo. 44 subjects will be randomly assigned using the RAS statistical software ) (size 4) will be assigned to intervention and placebo groups, and patients will be placed in blocks of 4 based on BMI and gender. In this study, the participants are randomly placed in two intervention and placebo groups so that researchers can compare different treatments. Researchers and participants cannot arbitrarily play a role in assigning people to groups. Random allocation of people to the intervention or placebo group will be done by an experienced expert, Blinding description: All subjects and researchers will be unaware of the existing grouping until the end of the study, and L-arginine supplement and placebo will be given to subjects once every 4 weeks by another person who has no knowledge of the research process. In order to evaluate the acceptance of the patients, a checklist will be prepared and given to the patients and they will be asked to record their daily consumption in it. In addition, in order to ensure the consumption of supplements, reminder messages will be sent to all patients every day. 2-3 Metabolic dysfunction-associated steatotic liver disease. Intervention 1: Intervention group: The intervention group will receive 3000 mg of arginine daily (3 tablets of 1000 mg) with water for 8 weeks. Arginine tablets are purchased from Karen. All patients will be monitored for pill consumption with a daily checklist and recall messages. Intervention 2: Control group: People in the placebo group will take a pill that is completely similar to the L-arginine supplement in terms of appearance, color and smell, daily in the same way for 8 weeks. Placebo pills are purchased from Karen Company. All patients will be monitored for pill consumption with a daily checklist and recall messages. Undecided - It is not yet known if there will be a plan to make this available Justification or reason for indecision in sharing IPD is Patient information will remain confidential. There is no further information.